First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis
NCT03559166
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
88
Enrollment
INDUSTRY
Sponsor class
Conditions
Fibrosis
Interventions
DRUG:
BLD-2660
Sponsor
Blade Therapeutics